MaRS EXCITE
EXCITE enables better health technologies to get to market faster for improved health outcomes.
What is EXCITE
MaRS Excellence in Clinical Innovation and Technology Evaluation (“EXCITE”) helps companies accelerate the adoption and reimbursement of innovative, disruptive health technologies through a single, harmonized, pre-market, evidence-based process.
Why EXCITE
EXCITE obviates the need for health technology assessment post-market through a collaborative, single, harmonized, pre-market process, which expedites market penetration and mitigates the risk of rejection.
Who is Involved
EXCITE is a collaboration between a range of stakeholders in the health technology sector.
Third Call for Innovation closed April 1, 2013
EXCITE’s third Call for Innovation closed on April 1, 2013. Applications are currently being reviewed and all applicants will be contacted with the results by late May.
Frequently Asked Questions
Q: How many Calls for Innovation will there be per year?
A: EXCITE anticipates that it will advertise two intake calls per year, one in the summer and the other in the winter.
